Crossreactivity of human versus swine platelet surface antigens is similar for glycoproteins Ib and IIIa, but not for the glycoprotein IIb/IIIa complex

Journal of Thrombosis and Thrombolysis

Volumn 5, Issue 1, 1998, Pages 37-41

  Serebruany, Victor L ^a   Ordonez, Jose V ^b   Yurovsky, Vladimir V ^b   Gurbel, Paul A ^a  

^a UNION MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Flow cytometry; Glycoprotein Ib; Glycoprotein IIb IIIa; Glycoprotein IIIa; Human; Platelets; Swine

Indexed keywords

ALPHA2 INTEGRIN; CD31 ANTIGEN; CD61 ANTIGEN; CD9 ANTIGEN; CROSS REACTING ANTIGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IIIA; MONOCLONAL ANTIBODY; PADGEM PROTEIN; THROMBOCYTE ANTIGEN; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG; VITRONECTIN; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SWINE;

EID: 0031884788     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008867930862     Document Type: Article

References (20)

1. Becker RC, Antiplatelet therapy in coronary heart disease. Emerging strategies for the treatment and prevention of acute myocardial infarction. Arch Path Lab Med 1993;117: 89-96.
2. The EPIC Investigators. Prevention of ischemic complications in high-risk angioplasty by a chimeric monoclonal antibody c7E3 Fab fragment directed against platelet glycoprotein IIb/IIIa receptor. N Engl J Med 1994;330:956-961.
3. Coller BS. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy, [From bench to bedside]. Circulation 1995;92:2S7a-2S80.
4. Backer RC, Tracy RP, Bovill EG, Mann KG, Ault K. The clinical use for assessing platelet activation in acute coronary syndromes. TIMI-III Thrombosis and Anticoagulation Group. Cor Art Dis 1994;5:339-345,
5. Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med 1994;123:728-740.
6. Atar D, Serebruany V, Poulton J, Godard J, Schneider A, Herzog WR. Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion, J Cardiovase Pharm 1994;24:608-611.
7. Geller RL, Rubinstein PF, Platt JL. Variation in expression of gp 115/135 on porcine platelets. Transplant Proc 1994;26: 1381,
8. Herzog WR, Schlossberg ML, MacMurdy KS, Edenbaum LB, Gerber MG, Vogel RA, Serebruany V L. Timing of magnesium therapy affects experimental infarct size. Circulation 1995;92:2622-2626.
9. Dodds WJ. The pig model for biomedical research. Fed Proc 1982;41:247-256,
10. Fedor JL, McIntosh DM, Rembert JC, Greenfeld JC. Coronary and transmural myocardial blood flow responses in awake domestic pigs. Am J Physiol 1978;235:H435-H444.
11. Softeland E, Framstad T, Thorsen T, Holmsen H. Porcine platelets in vitro and in vivo studies: Relevance to human thrombosis research. Eur J Haematol 1992:49:161-173.
12. Serebruany VL, Herzog WR, Gurbel PA, Schlossberg ML, Scott HJ, Vogel R.A. NPC 15669, an antiinflammatory leucine derivate, reduces in vitro platelet aggregability in both swine and human plasma. J Thromb Thrombolys 1995;1:171-178.
13. Gawaz M, Ott I, Reininger AJ, Neumann F.-J. Effects of magnesium on platelet aggregation and adhesion. Thromb Haemost 1994;72:912-918.
14. Bertha BG, Sill JC, Berger I, Foltz JD, Milde JH. High-dose droperidol protects against experimental coronary thrombosis in dogs and pigs and attenuates aggregation of porcine platelets and calcium mobilization in human platelets. Anesthesiology 1993;78:733-743.
15. Kinlough-Rathbone R, Rand ML, Packham MA. Rabbit and rat platelets do not respond to thrombin receptor peptides that activate human platelets. Blood 1993;82:103-106.
16. Yao SK, Ober JC, Gonenne A, et al. Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries. Circ Res 1993;73:952-967.
17. Platt JL, Vercelotti GM, Dalmasso AP. Transplantation of discordant xenografts: A review of progress. Immunol Today 1990:11:450-458.
18. Thibaudeau K, Anegon I, Lemauff B, Soulillou JP, Blanchard D. Human natural antibodies to porcine platelets. Transplantation 1994;57:1110-1115.
19. Altieri D, Capitanio A M, Mannucci P M. VWF contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Br J Haematol 1986;63:703-714.
20. Pareti FI, Mazzucato M, Bottini E, Mannucci PM. Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex. Br J Haematol 1992;82: 81-86.